Advertisement
Under the Bureau's plan, people over the age of 60 will be inoculated withthe influenza vaccine at no charge and primary and secondary school studentswill be inoculated with the influenza vaccine at a charge of 20 RMB per personwith allowances from the Bureau. The inoculation period is scheduled tocommence in October and will last until December 2007.
Advertisement
The Bureau selected Sinovac's bid. Up till now 140,000 adult doses ofAnflu at 34 RMB per dose were delivered to the Bureau. People in HaidianDistrict, Dongcheng District, Changping District and Fangshan District ofBeijing will be inoculated with Anflu, Sinovac's seasonal influenza vaccine.If the demand is increasing, the Bureau will order more flu vaccine.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccinesinclude Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) andAnflu(TM) (influenza). Sinovac is currently developing human vaccines againstthe H5N1 strain of pandemic influenza, Japanese encephalitis and SARS.Additional information about Sinovac is available on its website,http://www.sinovac.com . To be added to our distribution list, please email:[email protected].
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 X871 Fax: +86-10-6296-6910 Email: [email protected] Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: [email protected] [email protected]
SOURCE Sinovac Biotech Ltd.
